In the phase III EMBER-3 trial, patients with ER+ HER2- advanced BC had significantly longer PFS with imlunestrant compared to standard therapy, but only among those with ESR1 mutations; no benefit was observed in the overall population [15]. This evidence concerns the gene ESR1 and breast cancer.